|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 2 | HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series显示文摘 | Heike Grabsch Shivan Sivakumar Sally Gray Helmut E. Gabbert Wolfram Müller | 2010 | Cellular Oncology (-)2010，，1： | 3 |
| 3 | 糖尿病血管并发症的预防和早期发现显示文摘糖尿病能使人们的预期寿命缩短5~10年。尽管早发的心血管疾病是致残和致死的最常见原因,但糖尿病特异的微血管并发症(框图1)也是其中因素之一。糖尿病是全球肾脏替代治疗和65岁以下人群致盲的最常见病因,也是导致非外伤性截肢的最常见原因。根据我们现有的认识,就能预防或延迟以上这些严重事件中的大多数,或者将其危害降到最低。本文将集中阐述成人糖尿病血管并发症的预防、早期识别和初期的处理。 | Sally M Marshall Allan Flyvbjerg 谢超(译) | 2006 | 英国医学杂志中文版2006，9，6： | 3 |
| 4 | Tumor necrosis factor-α-G308A polymorphism is associated with liver pathological changes in hepatitis C virus patients显示文摘AIM To investigate the association of tumor necrosis factor alpha(TNFα)-G308 A polymorphism with different liver pathological changes in treatment-na?ve Egyptian patients infected with hepatitis C virus(HCV) genotype 4.METHODS This study included 180 subjects,composed of 120 treatment-na?ve chronic HCV patients with different fibrosis grades(F0-F4) and 60 healthy controls. The TNFα-G308 A region was amplified by PCR and the different genotypes were detected by restriction fragment length polymorphism analysis. The TNFα protein was detected by enzyme-linked immunosorbent assay. The influence of different TNFα-G308 A genotypes on TNFα expression and liver disease progression were statistically analyzed. The OR and 95%CI were calculated to assess the relative risk confidence.RESULTS Current data showed that the TNFα-G308 A SNP frequency was significantly different between controls and HCV infected patients(P = 0.001). Both the AA genotype and A allele were significantly higher in late fibrosis patients(F2-F4,n = 60) than in early fibrosis patients(F0-F1,n = 60)(P = 0.05,0.04 respectively). Moreover,the GA or AA genotypes increased the TNFα serum level greater than the GG genotype(P = 0.002). The results showed a clear association between severe liver pathological conditions(inflammation,steatosis and fibrosis) and(GA + AA) genotypes(P = 0.035,0.03,0.04 respectively). The stepwise logistic regression analysis showed that the TNFα genotypes(GA + AA) were significantly associated with liver inflammation(OR = 3.776,95%CI: 1.399-10.194,P = 0.009),severe steatosis(OR = 4.49,95%CI: 1.441-14.0,P = 0.010) and fibrosis progression(OR = 2.84,95%CI: 1.080-7.472,P = 0.034). Also,the A allele was an independent risk factor for liver inflammation(P = 0.003),steatosis(P = 0.003) and fibrosis(P = 0.014). CONCLUSION TNFα SNP at nucleotide-308 represents an important genetic marker that can be used for the prognosis of different liver pathological changes in HCV infected | Noha G Bader El Din Sally Farouk Reem El-Shenawy Marwa K Ibrahim Reham M Dawood Mostafa M Elhady Ahmed M Salem Naglaa Zayed Ahmed Khairy Mostafa K El Awady | 2016 | World Journal of Gastroenterology2016，22，34： | 3 |
| 5 | Inflammation and Alzheimer’s disease显示文摘 | Haruhiko Akiyama Steven Barger Scott Barnum Bonnie Bradt Joachim Bauer Greg M Cole Neil R Cooper Piet Eikelenboom Mark Emmerling Berndt L Fiebich Caleb E Finch Sally Frautschy W.S.T Griffin Harald Hampel Michael Hull Gary Landreth Lih–Fen Lue Robert Mrak | 2000 | Neurobiology of Aging2000，，3： | 2 |
| 6 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 7 | Phytoremediation of soil metals显示文摘 | Rufus L Chaney Minnie Malik Yin M Li Sally L Brown Eric P Brewer J Scott Angle Alan JM Baker | 1997 | Current Opinion in Biotechnology1997，，3： | 2 |
| 8 | HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series显示文摘 | Heike Grabsch Shivan Sivakumar Sally Gray Helmut E. Gabbert Wolfram Müller | 2010 | Cellular Oncology . 2010 (1-2)2010，，1： | 2 |
| 9 | Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford显示文摘BACKGROUND Vedolizumab(VDZ),a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative colitis(UC)patients.AIM To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter cohort involving two countries and to identify predictors of achieving remission.METHODS A retrospective review of Australian and Oxford,United Kingdom data for UC patients.Clinical response at 3 mo,endoscopic remission at 6 mo and clinical remission at 3,6 and 12 mo were assessed.Cox regression models and Kaplan Meier curves were performed to assess the time to remission,time to failure and the covariates influencing them.Safety outcomes were recorded.RESULTS Three hundred and three UC patients from 14 centres in Australia and United Kingdom,[60%n=182,anti-TNF naïve]were included.The clinical response was 79%at 3 mo with more Australian patients achieving clinical response compared to Oxford(83%vs 70%P=0.01).Clinical remission for all patients was 56%,62%and 60%at 3,6 and 12 mo respectively.Anti-TNF naive patients were more likely to achieve remission than exposed patients at all the time points(3 mo 66%vs 40%P<0.001,6 mo 73%vs 46%P<0.001,12 mo 66%vs 51%P=0.03).More Australian patients achieved endoscopic remission at 6 mo compared to Oxford(69%vs 43%P=0.01).On multi-variate analysis,anti-TNF naïve patients were 1.8(95%CI:1.3-2.3)times more likely to achieve remission than anti-TNF exposed(P<0.001).32 patients(11%)had colectomy by 12 mo.CONCLUSION VDZ was safe and effective with 60%of UC patients achieving clinical remission at 12 mo and prior anti-TNF exposure influenced this outcome. | Samba Siva Reddy Pulusu Ashish Srinivasan Krupa Krishnaprasad Daniel Cheng Jakob Begun CharlotteKeung Daniel Van Langenberg Lena Thin Tamara Mogilevski Peter De Cruz Graham Radford-Smith Emma Flanagan Sally Bell Soleiman Kashkooli Miles Sparrow Simon Ghaly Peter Bampton Elise Sawyer Susan Connor Quart-ul-ain Rizvi Jane M Andrews Gillian Mahy Paola Chivers Simon Travis Ian Craig Lawrance | 2020 | World Journal of Gastroenterology2020，26，30： | 2 |
| 10 | Prognostic signifi cance of visit-to-visit variability,maximum systolic blood pressure,and episodic hypertension显示文摘 | Peter M Rothwell Sally C Howard | 2010 | The Lancet2010，375，9718： | 1 |
| 11 | Predictors of adoption and maintainance of vigorous physical activity in men and women 显示文摘 | Sallis J F Hovel M F Hofstetter C R | 1992 | Preventive Medicine1992，21，： | 1 |
| 12 | Model Study of Laterally Loaded Piles 显示文摘 | Davisson M T Sally J R | 1970 | Journal of the Soil Mechancs and Foundation Division ASCE1970，96，5： | 1 |
| 13 | Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke显示文摘 | Rothwell Peter M Howard Sally C Dolan Eamon | 2010 | Lancet neurology2010，9，5： | 1 |
| 14 | Useof hospital beds : a cohort study of admissions to a provincial teaching hospital 显示文摘 | A Peter M Jill B Sally | 1988 | BMJ1988，297，8： | 1 |
| 15 | HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series显示文摘 | Heike Grabsch Shivan Sivakumar Sally Gray Helmut E. Gabbert Wolfram Müller | 2010 | Cellular Oncology (-)2010，，1： | 1 |
| 16 | HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value – conclusions from 924 cases of two independent series显示文摘 | Heike Grabsch Shivan Sivakumar Sally Gray Helmut E. Gabbert Wolfram Müller | 2010 | Cellular Oncology (-)2010，，1： | 1 |
| 17 | CVD synthetic diamond with unusual Diamond View image显示文摘 | SALLY E M | 2014 | Gems&Gemology2014，50，1： | 1 |
| 18 | Iron limits the cell division rate of Prochlorococcus in the eastern equatorial Pacific 显示文摘 | Elizabeth L M Sallie W C | 2000 | Limnol Oceanogr2000，45，5： | 1 |
| 19 | The distribution of dimethylsulfide,DMS,and dimethylsulfoniopropionate,DSMP,in waters of the Western Coast of Ireland显示文摘 | Sally Jo Palmer Locarnini Turner S M Liss P S | 1998 | Continental Shelf Research1998，18，： | 1 |
| 20 | Effects of early childhood psychosocial stimulation and nutritional supplementation on cognition and education in growth-stunted Jamaican children: prospective cohort study显示文摘 | Susan P Walker Susan M Chang Christine A Powell Sally M Grantham-McGregor | 2005 | The Lancet2005，，9499： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员